Trial Profile
A Multicentre, Non-Interventional, 3-Year Prospective Study Investigating the Real-Life Efficacy of Natalizumab and Integrated Patient Management Approach In Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRUST
- Sponsors Biogen
- 21 Apr 2016 First analysis of baseline data (n=427) presented at the 68th Annual Meeting of the American Academy of Neurology
- 11 Mar 2015 New trial record